Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant
Latest Information Update: 17 May 2022
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Aug 2020 Primary endpoint has been met. (Percentage of participants achieving sustained virologic response at 12 weeks after the end of all treatment (SVR12))
- 29 Aug 2020 Status changed from active, no longer recruiting to completed.
- 29 Aug 2020 Results (n=9) presented at The International Liver Congress 2020